Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | A benchmark for future disease-modifying therapies in Alzheimer’s disease

Todd E. Golde, MD, PhD, Emory University, Atlanta, GA, shares his thoughts on how to improve the development of disease modifying treatments for Alzheimer’s disease (AD) moving forward. For the first time, immune modulatory therapeutics are now available which tackle the underlying disease pathology. Prof. Golde notes that it will be crucial to use the success of these agents as a benchmark for the development of new therapeutics. From now on, investigative treatments will need to be at least as effective as what is currently available, and ideally more safe, accessible, or cost effective. By having a reference point, only the more promising agents will be taken forward to clinical development, improving the efficiency of drug development in AD. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.